Keyphrases
N-methyl-D-aspartate Receptor Antagonist
100%
Serotonin
100%
Novel Object Recognition
100%
Cognitive Impairment
100%
Psychosis
100%
N-methyl-D-aspartate
87%
Atypical Antipsychotics
37%
Locomotor Activity
37%
Serotonin 5-HT
25%
Antipsychotics
25%
5-HT2A Agonists
25%
5-HT2C Receptor
25%
Effective Treatment
12%
Nave
12%
Adverse Effects
12%
N-methyl-D-aspartate Receptor (NMDAR)
12%
Mechanism of Action
12%
Lurasidone
12%
Phencyclidine
12%
Pathophysiology of Schizophrenia
12%
Clozapine
12%
5-HT Receptors
12%
Serotonin 2A Receptor (5-HT2AR)
12%
Typical Antipsychotics
12%
5-HT6
12%
Constitutive Behavior
12%
Ketamine
12%
Novel Treatments
12%
5-HT2A Receptor
12%
Receptor Antagonism
12%
Competitive Antagonist
12%
5-HT1A Receptor Partial Agonist
12%
5-HT1A Agonist
12%
5-HT7 Receptor Antagonist
12%
Tandospirone
12%
MK-801
12%
M100907
12%
Dizocilpine
12%
D2 Antagonist
12%
ACP-103
12%
Induced Behavior
12%
Inverse Agonist
12%
D2 Receptor Antagonists
12%
Neutral Antagonist
12%
Model Psychosis
12%
Locomotor Impairment
12%
Pharmacology, Toxicology and Pharmaceutical Science
NMDA Receptor Antagonist
100%
Cognitive Defect
100%
Aspartic Acid
100%
Serotonin
100%
Atypical Antipsychotics
37%
Receptor
37%
Inverse Agonist
37%
Antipsychotic
25%
Typical Antipsychotic
25%
Receptor Antagonist
25%
Adverse Event
12%
Clozapine
12%
Ketamine
12%
Lurasidone
12%
Phencyclidine
12%
Partial Agonist
12%
Serotonin 1A Agonist
12%
Tandospirone
12%
Competitive Antagonist
12%
Volinanserin
12%
Pathophysiology
12%
Dizocilpine
12%